相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity
Hiroshi Yano et al.
IMMUNOLOGY (2019)
A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).
Shubham Pant et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM).
Julia Katharina Schwarze et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Ryan J. Sullivan et al.
NATURE MEDICINE (2019)
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas et al.
NATURE MEDICINE (2019)
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L. Topalian et al.
JAMA ONCOLOGY (2019)
Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors
Synnove Nymark Aasen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer
Ying Cheng et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
Liang Cheng et al.
MODERN PATHOLOGY (2018)
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Ryan J. Sullivan et al.
CANCER DISCOVERY (2018)
Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study
Raoul Tibes et al.
BRITISH JOURNAL OF CANCER (2018)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Michael B. Atkins et al.
CLINICAL CANCER RESEARCH (2018)
Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma
Pauline Tetu et al.
EUROPEAN JOURNAL OF CANCER (2018)
Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1
G. M. Haag et al.
EUROPEAN JOURNAL OF CANCER (2018)
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Margaret K. Callahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
Julia Boshuizen et al.
NATURE MEDICINE (2018)
Warming Cold Melanoma with TLR9 Agonists
Alissa Poh
CANCER DISCOVERY (2018)
The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
Marie-Anne Goyette et al.
CELL REPORTS (2018)
Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment
Natalia Pieper et al.
ONCOIMMUNOLOGY (2018)
Immunological effects of BRAF plus MEK inhibition
Paolo A. Ascierto et al.
ONCOIMMUNOLOGY (2018)
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Judith A. Seidel et al.
FRONTIERS IN ONCOLOGY (2018)
Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies
Allison S. Dobry et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Encorafenib and Binimetinib: First Global Approvals
Matt Shirley
DRUGS (2018)
A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.
John Sarantopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors.
James F. Spicer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial
Laurent Mortier et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma
Robert Hans Ingemar Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A randomized phase Ib/II study of the selective small molecule axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma.
Oddbjorn Straume et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ipilimumab and radiation in patients with unresectable melanoma brain metastases: A multicenter, open label, phase-2, Spanish Melanoma Group (GEM) study (NCT-2013-001132-22)
Jose A. Lopez-Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
The Role of Oncolytic Viruses in the Treatment of Melanoma
Claire-Audrey Y. Bayan et al.
CURRENT ONCOLOGY REPORTS (2018)
The age of enlightenment in melanoma immunotherapy
Mark R. Albertini
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
Luke D. Rothermel et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Neoadjuvant ipilimumab (3mg/kg or 10mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
Ahmad Tarhini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
Francesco Schettini et al.
FRONTIERS IN ONCOLOGY (2018)
Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma
Long Yuan et al.
JOURNAL OF CANCER (2018)
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
Stergios J. Moschos et al.
JCI INSIGHT (2018)
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
Alex A. Adjei et al.
INVESTIGATIONAL NEW DRUGS (2017)
Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
Antoine Millet et al.
MEDICINAL RESEARCH REVIEWS (2017)
Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
Noelle L. Williams et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition
Douglas B. Johnson et al.
JOURNAL OF IMMUNOTHERAPY (2017)
The NF1 gene in tumor syndromes and melanoma
Maija Kiuru et al.
LABORATORY INVESTIGATION (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2017)
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Ursula A. Germann et al.
MOLECULAR CANCER THERAPEUTICS (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Yaohua Xue et al.
NATURE MEDICINE (2017)
The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer
Diana J. Uribe et al.
PLOS ONE (2017)
NRAS-mutant melanoma: current challenges and future prospect
Eva Munoz-Couselo et al.
ONCOTARGETS AND THERAPY (2017)
Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAFV600E-mutant melanoma
Antoneicka L. Harris et al.
Oncotarget (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
Matthew J. Reilley et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Resistance to PD1/PDL1 checkpoint inhibition
Jake S. O'Donnell et al.
CANCER TREATMENT REVIEWS (2017)
MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors
Antonio M. Grimaldi et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.
Robert Hans Ingemar Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma
Sapna P. Patel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma
Jean-Pierre Delord et al.
CLINICAL CANCER RESEARCH (2017)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2017)
TAM Receptor Tyrosine Kinases in Cancer Drug Resistance
Mikaella Vouri et al.
CANCER RESEARCH (2017)
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
Naoya Yamazaki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
Adil Daud et al.
BRITISH JOURNAL OF CANCER (2017)
Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care
Ester Simeone et al.
BIODRUGS (2017)
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
Zeynep Eroglu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
Cristina Corno et al.
CURRENT MEDICINAL CHEMISTRY (2016)
A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors
A. Varga et al.
EUROPEAN JOURNAL OF CANCER (2016)
CD28 Costimulation: From Mechanism to Therapy
Jonathan H. Esensten et al.
IMMUNITY (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma
Susan M. Hiniker et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma
Sofie Wilgenhof et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development
James F. Blake et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F. Stephen Hodi et al.
LANCET ONCOLOGY (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Itay Tirosh et al.
SCIENCE (2016)
A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
Abhijit Ray et al.
ONCOTARGET (2016)
Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells
You-Take Oh et al.
SCIENTIFIC REPORTS (2016)
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
Asim Amin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
Andrew S. Brohl et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
The Receptor Tyrosine Kinase AXL in Cancer Progression
Erinn B. Rankin et al.
CANCERS (2016)
Biology and treatment of BRAF mutant metastatic melanoma
Benjamin Y. Kong et al.
MELANOMA MANAGEMENT (2016)
Resistant mechanisms to BRAF inhibitors in melanoma
Jose Luis Manzano et al.
ANNALS OF TRANSLATIONAL MEDICINE (2016)
AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
Moshe Elkabets et al.
CANCER CELL (2015)
Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
Gatien Moriceau et al.
CANCER CELL (2015)
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
N. Yamazaki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Willy Hugo et al.
CELL (2015)
A ROS-Activatable Agent Elicits Homologous Recombination DNA Repair and Synergizes with Pathway Compounds
Fathima Shazna Thowfeik et al.
CHEMBIOCHEM (2015)
Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
Michele Maio et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor-Resistant Cutaneous Melanomas
Jinhua Wang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
The multi-faceted roles of the PI3K-AKT pathway in melanoma
Michael A Davies
Journal of Translational Medicine (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
I-K Park et al.
LEUKEMIA (2015)
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
Francesco Spagnolo et al.
ONCOTARGETS AND THERAPY (2015)
Nivolumab in NSCLC: latest evidence and clinical potential
Raghav Sundar et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
A. M. Di Giacomo et al.
ANNALS OF ONCOLOGY (2015)
Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
Matteo S. Carlino et al.
CLINICAL CANCER RESEARCH (2015)
Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
Lindsey N. Micel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
Zheng Zhao et al.
ACS CHEMICAL BIOLOGY (2014)
Reactive Oxygen Species-Responsive Protein Modification and Its Intracellular Delivery for Targeted Cancer Therapy
Ming Wang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Outcomes of Patients With Metastatic Melanoma Treated With Immunotherapy Prior to or After BRAF Inhibitors
Allison Ackerman et al.
CANCER (2014)
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Moriah H. Nissan et al.
CANCER RESEARCH (2014)
The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
Ian R. Watson et al.
CANCER RESEARCH (2014)
Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation
D. V. Chan et al.
GENES AND IMMUNITY (2014)
Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma A Randomized Clinical Trial
F. Stephen Hodi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
An Activatable Prodrug for the Treatment of Metastatic Tumors
Eun-Joong Kim et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results
Richard Kefford et al.
Journal of Translational Medicine (2014)
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Deborah J. L. Wong et al.
MOLECULAR CANCER (2014)
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun et al.
NATURE (2014)
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
Magdalena Paolino et al.
NATURE (2014)
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Georgina V. Long et al.
NATURE COMMUNICATIONS (2014)
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Judith Mueller et al.
NATURE COMMUNICATIONS (2014)
MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
Nikhil Wagle et al.
CANCER DISCOVERY (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
David J. Konieczkowski et al.
CANCER DISCOVERY (2014)
Safety and clinical activity of combining systemic ipilimumab with isolated limb infusion in patients with in-transit melanoma.
Charlotte Eielson Ariyan et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
D. McDermott et al.
ANNALS OF ONCOLOGY (2013)
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
Jedd D. Wolchok et al.
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN USA 2012 (2013)
An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2013)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2013)
Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma
Lawrence N. Kwong et al.
CLINICAL CANCER RESEARCH (2013)
Resistance to BRAF-targeted therapy in melanoma
Ryan J. Sullivan et al.
EUROPEAN JOURNAL OF CANCER (2013)
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
Paolo A. Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
Kerstin Trunzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Erick J. Morris et al.
CANCER DISCOVERY (2013)
Mitochondrial oxidative stress is the achille's heel of melanoma cells resistant to Braf-mutant inhibitor
Paola Corazao-Rozas et al.
ONCOTARGET (2013)
Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype
Mickal Ohanna et al.
ONCOTARGET (2013)
A Landscape of Driver Mutations in Melanoma
Eran Hodis et al.
CELL (2012)
Rac signaling in breast cancer: A tale of GEFs and GAPs
Eva Wertheimer et al.
CELLULAR SIGNALLING (2012)
The role of BRAF V600 mutation in melanoma
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante et al.
LANCET ONCOLOGY (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
Sergey I. Nikolaev et al.
NATURE GENETICS (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Reactive oxygen species: from health to disease
Katharine Brieger et al.
SWISS MEDICAL WEEKLY (2012)
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
Hubing Shi et al.
NATURE COMMUNICATIONS (2012)
ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage
Xiaohua Peng et al.
THERAPEUTIC DELIVERY (2012)
Mutant BRAF Melanomas-Dependence and Resistance
Poulikos I. Poulikakos et al.
CANCER CELL (2011)
Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer
Peter D. Boasberg et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma
Evan M. Hersh et al.
INVESTIGATIONAL NEW DRUGS (2011)
Human Cutaneous Melanomas Lacking MITF and Melanocyte Differentiation Antigens Express a Functional Axl Receptor Kinase
Marialuisa Sensi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
Omar S. Qureshi et al.
SCIENCE (2011)
Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells
Annette S. Little et al.
SCIENCE SIGNALING (2011)
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
S. J. O'Day et al.
ANNALS OF ONCOLOGY (2010)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
John M. Kirkwood et al.
CLINICAL CANCER RESEARCH (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
E6201 [(3S,4R,5Z,8S,9S,11E)-14-(Ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione], a Novel Kinase Inhibitor of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase (MEK)-1 and MEK Kinase-1: In Vitro Characterization of Its Anti-Inflammatory and Antihyperproliferative Activities
Masaki Goto et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations
Ludovica Ciuffreda et al.
NEOPLASIA (2009)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut et al.
CANCER RESEARCH (2008)
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
Jaclyn LoPiccolo et al.
DRUG RESISTANCE UPDATES (2008)
The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells
Joe W. Ramos
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2008)
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Keiran S. M. Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2008)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
Mechanisms of disease - Melanoma
Arlo J. Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis
S Kawanishi et al.
BIOLOGICAL CHEMISTRY (2006)
Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity
EO Hileman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
PTEN signaling pathways in melanoma
H Wu et al.
ONCOGENE (2003)
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
CC Stamper et al.
NATURE (2001)
分享论文
